Security Snapshot

Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) Institutional Ownership

CUSIP: 22978P106

13F Institutional Holders and Ownership History from Q1 2018 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

51

Shares (Excl. Options)

21,281,307

Price

$0.23

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
CUE on Nasdaq
Shares outstanding
43,411,663
Price per share
$0.67
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
21,281,307
Total reported value
$4,893,060
% of total 13F portfolios
0%
Share change
-395,525
Value change
-$151,601
Number of holders
51
Price from insider filings
$0.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 22978P106.
  • 51 institutions reported positions in Q1 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 48 to 51 between Q4 2025 and Q1 2026.
  • Reported value moved from $6,659,692 to $4,893,060.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 51 institutions filings for Q1 2026.

Open SEC Evidence

Security key

22978P106

Latest holder period

Q1 2026

13F holders

51

13D/G owners

3

CIK / CUSIP context first

Open Q1 2026 holders CUE full holder history Cue Biopharma, Inc. SEC filings Cue Biopharma, Inc. company facts Cue Biopharma, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Bleichroeder LP 10% 0% $5,269,789 6,127,662 0% Bleichroeder LP 19 Mar 2025
STROME MARK E 5% $1,862,968 2,166,242 Mark E. Strome 14 Nov 2022
Slate Path Capital LP 1.4% $790,199 918,836 Slate Path Capital LP 31 Dec 2024

As of 31 Mar 2026, 51 institutional investors reported holding 21,281,307 shares of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE). This represents 49% of the company’s total 43,411,663 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Bleichroeder LP 16% 6,819,164 0% 0.27% $1,567,726
GC Wealth Management RIA, LLC 11% 4,631,644 0% 0.04% $1,064,815
VANGUARD CAPITAL MANAGEMENT LLC 5.7% 2,457,452 0% 0% $565,214
Lion Point Capital, LP 5.1% 2,202,854 0% 3% $506,436
GEODE CAPITAL MANAGEMENT, LLC 2.5% 1,064,690 +33% 0% $244,800
VANGUARD FIDUCIARY TRUST CO 1.3% 543,585 0% 0% $125,025
Robertson Stephens Wealth Management, LLC 1.1% 478,500 0% 0% $110,007
BlackRock, Inc. 1% 449,161 -0% 0% $103,261
Texas Capital Bank Wealth Management Services Inc 0.92% 397,421 -9.8% 0.01% $91,367
ANGELES WEALTH MANAGEMENT, LLC 0.71% 310,000 0% 0% $71,269
ADVISORY RESEARCH INC 0.59% 257,225 0% 0.01% $59,136
STIFEL FINANCIAL CORP 0.57% 246,556 0% 0% $56,683
RENAISSANCE TECHNOLOGIES LLC 0.49% 213,828 -10% 0% $49,159
BANK OF AMERICA CORP /DE/ 0.48% 207,708 +0.07% 0% $47,565
STATE STREET CORP 0.41% 179,353 0% 0% $41,233
DIADEMA PARTNERS LP 0.3% 131,997 0.01% $30,346
NORTHERN TRUST CORP 0.22% 94,606 -6.3% 0% $21,750
UBS Group AG 0.2% 88,350 +89% 0% $20,320
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 0.18% 79,500 0% 0% $18,277
ADVISORTRUST PARTNERS, LLC 0.12% 50,000 0% $11,495
Virtu Financial LLC 0.11% 49,553 0% $11,000
Sigma Planning Corp 0.09% 38,750 -5.6% 0% $8,909
GOLDMAN SACHS GROUP INC 0.08% 34,151 +138% 0% $7,851
Persistent Asset Partners Ltd 0.08% 33,369 0% $7,672
Visionary Wealth Advisors 0.07% 29,285 0% $6,733

Institutional Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 21,281,307 $4,893,060 -$151,601 $0.23 51
2025 Q4 21,788,519 $6,659,692 +$1,059,340 $0.31 48
2025 Q3 18,058,960 $12,982,249 +$519,709 $0.72 52
2025 Q2 17,351,508 $11,856,298 +$3,983,649 $0.68 46
2025 Q1 11,402,706 $10,374,424 -$452,161 $0.91 49
2024 Q4 11,759,494 $12,816,995 -$1,528,241 $1.09 55
2024 Q3 13,910,388 $10,533,734 -$288,922 $0.76 50
2024 Q2 13,807,875 $17,121,019 -$3,730,383 $1.24 72
2024 Q1 16,387,055 $30,971,606 +$2,715,659 $1.89 74
2023 Q4 14,886,167 $39,304,464 +$2,537,424 $2.64 80
2023 Q3 14,014,675 $32,148,839 -$634,604 $2.30 75
2023 Q2 13,849,849 $50,545,862 +$6,687,288 $3.65 77
2023 Q1 12,055,434 $43,037,472 -$2,540,576 $3.57 62
2022 Q4 12,761,302 $36,370,518 +$155,907 $2.85 60
2022 Q3 12,797,287 $28,665,093 -$2,995,285 $2.23 61
2022 Q2 14,083,808 $35,042,763 -$10,988,434 $2.49 68
2022 Q1 17,812,661 $87,010,965 +$4,491,451 $4.88 97
2021 Q4 16,533,577 $187,228,947 -$11,058,319 $11.31 88
2021 Q3 16,892,813 $245,597,815 -$23,967,610 $14.57 87
2021 Q2 18,582,224 $216,368,968 -$2,774,327 $11.65 89
2021 Q1 18,817,560 $229,653,033 -$6,452,286 $12.20 88
2020 Q4 19,314,982 $241,658,115 -$3,019,434 $12.51 94
2020 Q3 19,517,235 $293,948,076 +$49,950,366 $15.05 90
2020 Q2 16,042,165 $393,156,090 +$84,955,728 $24.51 99
2020 Q1 13,033,369 $184,956,981 +$36,613,314 $14.19 72
2019 Q4 10,554,208 $167,568,706 +$63,118,277 $15.88 60
2019 Q3 6,080,606 $51,262,809 +$13,288,944 $8.43 44
2019 Q2 4,501,012 $40,453,546 +$9,997,120 $8.99 36
2019 Q1 3,453,175 $26,693,413 +$1,831,681 $7.73 37
2018 Q4 3,229,210 $15,171,419 -$2,037,779 $4.70 34
2018 Q3 3,579,962 $32,396,140 +$3,237,621 $9.05 36
2018 Q2 3,148,586 $37,344,175 +$15,445,827 $11.86 37
2018 Q1 1,844,607 $25,915,405 +$25,915,405 $14.05 28
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .